August 17, 2023 7:56am

Again, I reiterate - I’m looking at entry points

If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.

Pre-open Indications: 2 Negative, 2 Positive

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!  Never leave an investor uninformed! 

Never leave an investor uninformed!

8:00 a.m. edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on what will happen behind the headlines today, not tomorrow or yesterday

 

Dow futures are UP +0.35% or (+86 point), S&P futures are UP +o.21% or (+9 points) and NASDAQ futures are UP +0.19% or (+28 points) early in the pre-open – so far

Stock futures nudged higher Thursday

Asia-Pacific markets were mixed,

Asia-Pacific markets were mixed

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Wednesday, indexes feel as the Dow closed DOWN -180.65 or -0.52%, the S&P closed DOWN -33.53 or -0.76% while the Nasdaq closed DOWN -156.42 points (-1.15%)

Yesterday, the reeling stock market rally saw significant losses, with the Nasdaq starting to lose sight of its 50-day line as Fed meeting minutes showed policymakers fearing "upside risks" to inflation. The 10-year Treasury hit its highest level since 2008.

Economic Data Docket: weekly jobless claims report. The Philadelphia Fed will disclose the Philly Fed manufacturing index for August.

 

Wednesday’s (8/16) RegMed Investors’ (RMi) closing bell: “sector equities sell-off again” … https://www.regmedinvestors.com/articles/13081

 

Ebb and flow:

Q3: August – 2 positive and 10 negative closes

•              July - 1 holiday, 12 positive and 8 negative close

Q2/23 -

•              June -1 Holiday, 8 negative and 11 positive closes

•              May – 10 negative and 12 positive closes

•              April ended - 1 holiday, 8 positive close and 11 negative closes

Q1/23 –-

•              March – ended with 10 positive and 13 negative closes

•              February – 1 holiday, 2 vacation, 7 negative and 8 positive closes

•              January – 2 holidays, 11 positive and 9 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Wednesday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Positive Indications:

Blueprint Medicine (BPMC) closed down Wednesday -$1.85 after Tuesday’s -0.19 and Monday’s +$1.88 with a positive +$0.99 or +2% afterhours indication.

Ultragenyx Pharmaceuticals (RARE) closed down -$1.27 after Tuesday’s +$0.49 and Monday’s +$1.58 With a positive +$0.74 or +1.99% aftermarket indication.

 

Negative Indications:

Wednesday’s closing price, aftermarket dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed up +$2.30 after Tuesday’s -$1.22 and Monday’s -$4.44 with a negative -$2.42 or -1.335 aftermarket indication.

Ionis Pharmaceuticals (IONS) closed down Wednesday -$0.45 after Tuesday’s -$0.34 with a negative -$0.35 or -0.88% aftermarket indication

 

The BOTTOM LINE:

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all, as I try to keep it simple and short!

Risk denotes the uncertainty of an outcome.

Cell and gene therapy stocks have been suffering through a rocky August, with the “players” well in negative territory for the month. Valuations have come down from their heights.

There are currently hardly any catalyst, which in turn gives the weak economic forecasts more room to move share pricing.

It “ain’t” been a good August for the cell and gene therapy sector as it suffers 2 positive and 9 negative closes so far.

There's ALSO nothing wrong with standing pat in the short run, holding on to sizable existing exposure.

I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.